Novo Nordisk A/SNVONYSE
Loading
Revenue PerformanceStrong
Percentile Rank100
3Y CAGR+18.9%
5Y CAGR+18.5%
Studio
Year-over-Year Change

Total revenue from sales of goods and services

3Y CAGR
+18.9%/yr
vs +12.2%/yr prior
5Y CAGR
+18.5%/yr
Consistent
Acceleration
+6.7pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.3x
Strong expansion
Streak
8 yr
Consecutive growthStrong
PeriodValueYoY Change
2025$297.20B+2.3%
2024$290.40B+25.0%
2023$232.26B+31.3%
2022$176.95B+25.7%
2021$140.80B+10.9%
2020$126.95B+4.0%
2019$122.02B+9.1%
2018$111.83B+0.1%
2017$111.70B-0.1%
2016$111.78B-